Nanjing Norman Biological Technology Co., Ltd

What Nanjing Norman Biological Technology Co., Ltd does

Nanjing Norman Biological Technology Co., Ltd is a privately held Chinese in-vitro diagnostics (IVD) company founded in 2008 and headquartered at No. 197 Pharmaceutical Valley Road, Jiangbei New Area, Nanjing, Jiangsu Province, operating from a 30,000 m2 site that combines manufacturing and R&D. Its core technology is chemiluminescence immunoassay (CLIA), underpinned by more than 16 years of platform development, complemented by immunofluorescence (FIA), PCR, colloidal gold lateral flow, biochemistry, hematology, and urine-analysis modalities. The company's flagship technical achievement is a rapid CLIA system first released globally in 2017 that delivers results in under seven minutes and supports whole-blood testing without centrifugation, with a test menu exceeding 130 parameters on the rapid platform and a separate NORMAN-CL211 platform unveiled at Medlab Middle East 2025.

The company's product portfolio is organized across IVD analyzers and reagents (CLIA, FIA, PCR, biochemistry, glycohemoglobin, hematology, urine), colloidal gold rapid tests (COVID-19, HIV, hepatitis, malaria, dengue, influenza), healthcare devices (Continuous Glucose Monitoring, smart watch, digital hearing aid), and IVD raw materials (independently developed antigens, antibodies, magnetic beads produced with an SPF-grade animal experiment center). Norman generates revenue through hardware sales of analyzers, sales of diagnostic reagents, raw-material supply, and healthcare-device sales. It goes to market via a direct enterprise sales force targeting tertiary hospitals in China and through international distribution across more than 20 countries in Asia, Europe, and South America, supplemented by exhibition-driven sales at CMEF, CACLP, Medlab Middle East, and WHX events. The company is certified as a National High-Tech Enterprise and a National Specialized & Sophisticated Enterprise, and has CE-marked, ISO 13485-certified products, with no public listing, ticker, or external institutional funding disclosed in the available data.

Name

Nanjing Norman Biological Technology Co., Ltd

Legal name

Nanjing Norman Biological Technology Co., Ltd

Website

https://normanbio.com

Company type

Private

Founded year

2008

Operating status

Operating

Headcount range

1–10 employees

Short description

Nanjing Norman Biological Technology Co., Ltd is a privately held Chinese IVD company founded in 2008 that develops and sells CLIA, FIA, and PCR analyzers and reagents, colloidal gold rapid tests, and healthcare devices, serving 700+ tertiary hospitals in China and operating in over 20 countries.

Ownership category

akta.pro rank

Product category

In Vitro Diagnostics (IVD) Instruments and Reagents

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Analytical Laboratory Instrument Manufacturing (334516), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Laboratory Analytical Instruments (3826), Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

IVD Reagents, Assay Kits & Consumables (Non-instrument) (HLAHAAAM)

akta.pro secondary industries

Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls) (HLAAAMAL), Laboratory Automation, Sample Prep & Liquid Handling (IVD Lab Diagnostics) (HLAHAAAN), Clinical Chemistry & Hematology Diagnostics (automated analyzers, blood testing) (HLAAALAH), Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes) (HLAGAIAI)

Keywords

• In vitro diagnostics
• Chemiluminescence immunoassay
• Immunofluorescence analyzers
• PCR diagnostic systems
• Diagnostic reagents

Headquarters

HQ city

Nanjing, Jiangsu

HQ country

China

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. IVD Analyzers and Instruments: Sale of immunodiagnostic analyzers including CLIA, FIA, and PCR systems along with instrument equipment.
2. IVD Reagents: Sale of diagnostic reagents covering multiple disease categories including inflammation, thyroid, cardiovascular, sex hormone, tumor, infection disease, autoimmune, anemia, growth, bone metabolism, cytokine, hypertension, diabetes, coagulation, kidney, hepatic fibrosis and drug monitoring.
3. IVD Raw Materials: Sale of raw materials including antigens, antibodies, and magnetic beads for IVD manufacturing.
4. Healthcare Products: Sale of healthcare products including Continuous Glucose Monitoring systems.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Core offering

Nanjing Norman Biological Technology Co., Ltd manufactures and sells in vitro diagnostic (IVD) analyzers and reagents, with chemiluminescence immunoassay (CLIA) as its core technology. Its product portfolio includes rapid CLIA analyzers delivering results in under 7 minutes, fluorescence immunoassay (FIA) analyzers, PCR systems, automated biochemistry analyzers, hematology analyzers, urine analyzers, colloidal gold rapid test kits, and continuous glucose monitoring systems. The company also produces IVD raw materials and serves hospitals and laboratories across China and more than 20 international markets.

Product overview

Nanjing Norman Biological Technology Co., Ltd is an IVD company offering a comprehensive portfolio of diagnostic products organized around three main categories: IVD analyzers, IVD reagents, and healthcare devices. The analyzer portfolio includes Rapid Chemiluminescent Immunoassay (CLIA) analyzers (desktop and rapid testing platforms), Portable Fluorescence Immunoassay (FIA) analyzers, Auto Biochemistry Analyzers, Glycohemoglobin Analyzers, Real-Time PCR systems, Hematology Analyzers, and Urine Analyzers. The reagent portfolio covers over 140 test parameters across CLIA and colloidal gold lateral flow formats for infectious diseases (COVID-19, HIV, Hepatitis, Malaria, Dengue), cardiovascular markers, inflammation, thyroid function, tumor markers, and more. Healthcare devices include Continuous Glucose Monitoring Systems, Smart Watches, Digital Hearing Aids, and accessories such as sampling swabs and incubators. The company operates IVD raw materials production including antigens, antibodies, and magnetic beads. The product ecosystem is designed for various healthcare settings from large hospitals to small clinics, with rapid testing capabilities delivering results in as little as 7 minutes.

Differentiator

Problem solved

Functional benefit

Products and services

• Rapid Chemiluminescent Immunoassay (CLIA) Analyzer Desktop rapid chemiluminescence immunodiagnostic platform designed for outpatient, emergency, and mid-sized laboratories. Features both rapid mode (results in 7 minutes) and conventional testing mode with whole blood compatibility.
• NORMAN-CL211 Rapid Chemiluminescence Platform Desktop rapid chemiluminescence platform targeting outpatient, emergency departments, and chest pain centers, with whole blood testing capability and over 140 test parameters in conventional mode.
• Portable Fluorescence Immunoassay (FIA) Analyzer Portable one-channel fluorescence immunoassay analyzer designed for small clinics, combining space-saving footprint with a comprehensive test menu.
• Continuous Glucose Monitoring (CGM) System Healthcare device for continuous glucose monitoring, described as the gold standard for diabetes diagnosis.
• UKCA 8800 Auto Biochemistry Analyzer Fully automated microfluidic chemistry analyzer for clinical biochemistry testing.
• UKGH-200 Glycohemoglobin Analyzer Analyzer for HbA1c testing, used for diabetes diagnosis and monitoring.
• UKRT Qube Real-Time PCR Portable PCR device for on-site testing, enabling rapid molecular diagnostics.
• UKRT Mini Real-Time Fluorescence Quantitative PCR 16-channel real-time fluorescence quantitative PCR system for molecular diagnostics.
• Huma 5000 Multiparameter Hematology Analyzer 5-part differential hematology analyzer with single-test reagent packaging for comprehensive blood analysis.
• WX-100 Urine Analyzer Automated urine analyzer for clinical diagnostics.
• CLIA Test Menu Reagents Comprehensive chemiluminescence immunoassay reagent menu covering multiple disease categories including inflammation, thyroid, cardiovascular, sex hormone, tumor, infection, autoimmune, anemia, bone metabolism, and more.
• Colloidal Gold Rapid Test Kits Portfolio of colloidal gold immunochromatography rapid test kits for infectious disease detection including COVID-19 antigen (nasal, saliva, anterior swab), COVID-19 neutralizing antibody, HIV Ag/Ab combo, Malaria Pf/Pv, Dengue NS1, HBsAg, and HCV Ab tests.
• IVD Raw Materials IVD raw materials including independently developed antigens, antibodies, and magnetic beads, produced with access to an SPF-grade animal experiment center.
• Digital Hearing Aid Digital hearing assistance device for individuals with hearing impairment.
• Smart Watch Wearable healthcare device for health monitoring.

Quantifiable outcome

• Results delivered in under 7 minutes for rapid CLIA testing
• +2 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• Exhibition Attendees at CMEF 2025minorOthers · 8 April 2025Participated in China International Medical Equipment Fair (CMEF) in Shanghai, engaging with industry leaders, potential partners, and healthcare professionals from over 30 countries. Exhibition served as platform for dialogues with global clients and cross-border insights.

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

Regional players

• KingMed Diagnostics: China's largest independent medical laboratory network, comparable as a buyer and ecosystem participant for IVD analyzers/reagents rather than a head-to-head manufacturer peer.

Direct peers

• Shenzhen New Industries Biomedical Engineering (Snibe): Leading Chinese chemiluminescence immunoassay (CLIA) platform provider competing head-to-head with Norman in hospital immunology diagnostics in China and overseas.
• Wondfo Biotech: Chinese IVD and POCT company with colloidal-gold rapid tests, FIA analyzers and CLIA products, overlapping Norman's colloidal-gold and immunoassay product lines.
• Maccura Biotechnology: Chinese IVD manufacturer with immunoassay, clinical chemistry and PCR systems serving Chinese hospital laboratories, comparable in scale and product breadth to Norman.
• DiaSorin: Specialist in clinical immunoassays with CLIA-based platforms (LIAISON) for infectious disease, endocrinology and cardiac markers, comparable to Norman's CLIA franchise.
• Autobio Diagnostics: Major Chinese IVD company with a broad CLIA/immunoassay analyzer and reagent menu serving tertiary hospitals and clinical labs, directly overlapping Norman's core offering.

Broad incumbents

• Abbott Diagnostics: Global IVD incumbent operating ARCHITECT and Alinity immunoassay systems that directly compete with Norman's CLIA analyzers in hospital and reference-lab settings.
• Siemens Healthineers: Operates the ADVIA Centaur and Atellica immunoassay platforms, overlapping Norman's CLIA offering as a global incumbent in clinical diagnostics.
• Roche Diagnostics: Global IVD leader with extensive CLIA/electrochemiluminescence platforms installed in tertiary hospitals worldwide; competes with Norman in the same clinical immunoassay segment.
• Mindray: Large Chinese medical-device incumbent offering IVD analyzers, reagents and a full lab-instrument portfolio, competing with Norman across multiple device and reagent categories.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/NormanLtd33001
• YouTubeyoutube.com/@normanbiological?si=UQ9ortKyll_MW-c2
• Facebookfacebook.com/normanbiological
• LinkedInlinkedin.com/company/nanjing-norman-biological

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nanjing Norman Biological Technology Co., Ltd